Lipid Disorders
News
Health care costs nearly doubled for patients with NAFLD
Both hospitalizations and outpatient visits accounted for the increased costs.
From the Journals
Obesity can shift severe COVID-19 to younger age groups
“This could turn into kind of a viral replication depot. You may well be brewing more virus as a component of obesity.”
Conference Coverage
Evolocumab safe, well-tolerated in HIV+ patients
PCSK9 inhibition may play a major role in curbing markedly increased cardiovascular risk in people living with HIV.
From the Journals
Adolescent obesity, diabetes linked to atherosclerotic signs
A 5-year longitudinal study reports that obesity and type 2 diabetes may predispose adolescents to early signs of atherosclerosis.
From the Journals
FOURIER: Evolocumab follow-up shows no cognitive adverse effects
A cognition survey of more than 22,000 FOURIER patients showed no compromise linked to evolocumab or sharply cut LDL-C levels.
Conference Coverage
High rate of fatty liver disease found among 9/11 first responders
This is likely because of toxin exposure at ground zero, which can cause a subtype of NAFLD known as toxin-associated fatty liver disease.
From the Journals
Noninvasive tests boost risk stratification in obese compensated ACLD
Study finds noninvasive tests in combination with probes can improve risk stratification in obese compensated advanced chronic liver disease...
From the Journals
Consensus recommendations on AMI management during COVID-19
The ACC, ACEP, and SCAI recommend a systematic approach for the care of patients with an acute myocardial infarction during the COVID-19 pandemic...
Conference Coverage
PCSK9 inhibitors unexpectedly link with lower VTE, aortic stenosis
From the Journals
Year-long synbiotic regimen fails to improve NAFLD
Mean liver fat content was reduced by 4% in the synbiotic group, compared with 6% in the placebo group, a difference that was not statistically...
From the Journals
Noninvasive fibrosis scores not sensitive in people with fatty liver disease and T2D
Alternatives to liver biopsy are less than ideal for detecting advanced fibrosis in patients with underlying diabetes.